Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tid.13211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.
Hepatol Commun
March 2025
Department of Clinical Microbiology & Immunology, Janssen Pharmaceutica NV, a Johnson & Johnson Company, Clinical Microbiology & Immunology Beerse, Belgium.
Background: In the nucleos(t)ide analog (NA)-control arm of the REEF-2 study (NCT04129554), virologic relapse (confirmed increase in HBV DNA >2000 IU/mL) and biochemical flare (ALT increases ≥3× upper limit of normal) were frequently observed after stopping NA treatment. We characterized the posttreatment virologic relapses and biochemical flares and assessed their association with end-of-treatment (EOT) HBV serum markers.
Methods: In REEF-2, a randomized-controlled study, virologically suppressed HBeAg-negative patients stopped treatment at week 48, followed by 48 weeks of follow-up.
Vertical Transmission in Mothers Taking TAF With Exceptionally High Viral Load.
J Viral Hepat
March 2025
Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, NYU School of Medicine, Flushing, New York, USA.
Published studies on tenofovir alafenamide (TAF) therapy for preventing vertical transmission of hepatitis B virus (HBV) have primarily enrolled mothers with viremic levels of approximately 7 log IU/mL. This study aimed to evaluate the efficacy and safety of TAF therapy in preventing mother-to-child transmission (MTCT) in mothers with exceptionally high viral loads, defined as HBV DNA levels > 2,000,000 IU/mL. Hepatitis B e antigen (HBeAg)-positive mothers with HBV DNA levels > 2,000,000 IU/mL were prospectively enrolled from four hospitals and initiated on TAF therapy between gestational weeks 26 and 28, continuing until delivery.
View Article and Find Full Text PDFEditorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors.
Aliment Pharmacol Ther
February 2025
Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors-Authors' Reply.
Aliment Pharmacol Ther
February 2025
School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Impact of HBV serological status on HIV virological efficacy of two-drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir.
HIV Med
February 2025
Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario "Agostino Gemelli", IRCCS, Rome, Italy.
Objectives: This study aimed to evaluate the HIV virological efficacy of two-drug regimens (2DR) with lamivudine (3TC) and dolutegravir (DTG) in people with HIV (PWH), classified by their hepatitis B virus (HBV) serological status. Specifically, it explored whether isolated anti-hepatitis B core (anti-HBc) positivity impacts virological outcomes.
Methods: A retrospective observational study was conducted at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, enrolling 606 virologically suppressed (HIV-RNA < 50 copies/mL) PWH who switched to a 2DR regimen with 3TC/DTG.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!